Clinical experience of levetiracetam monotherapy for adults with epilepsy: 1-year follow-up study

Taoufik M. Alsaadi, Alan Shatzel, Anna Vinter Marquez, Julie Jorgensen, Sarah E Tomaszewski Farias

Research output: Contribution to journalArticle

31 Scopus citations


We identified 46 patients with a history of partial seizures, with and without secondarily generalization, who received levetiracetam (LEV) (Keppra®) monotherapy. Patients began LEV either as first line therapy (n = 11) or were converted to LEV monotherapy (n = 35) after failing prior antiepileptic medications (AEDs). Patients were followed up to 12 months after LEV started. The majority of these patients were able to continue on LEV and a small number of patients discontinued LEV secondary to lack of efficacy. One third of the non-seizure free group at 6 months of follow-up had worse seizure control at 12 months and two thirds had the same or better seizure control. Our 1-year follow-up data of LEV as monotherapy suggests that LEV can be effective and well tolerated in adults with either new or difficult to control epilepsy. A prospective, large, long-term double-blind study is needed to confirm this finding.

Original languageEnglish (US)
Pages (from-to)139-142
Number of pages4
Issue number2
StatePublished - Mar 2005



  • Levetiracetam
  • Monotherapy
  • Partial seizures

ASJC Scopus subject areas

  • Clinical Neurology
  • Pediatrics, Perinatology, and Child Health
  • Neurology
  • Psychology(all)

Cite this